← Back to Search

Monoclonal Antibodies

XmAb20717 for Thymoma (DUET-2 Trial)

Phase 1
Waitlist Available
Research Sponsored by Xencor, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 56 days
Awards & highlights

DUET-2 Trial Summary

This trial is testing a new drug, XmAb20717, to see if it is safe and effective in treating advanced solid tumors.

Eligible Conditions
  • Thymoma
  • Kidney Cancer
  • Prostate Cancer
  • Solid Tumors
  • Small Cell Lung Cancer
  • Endometrial Cancer
  • Colorectal Cancer
  • Penile Squamous Cell Carcinoma
  • Neuroendocrine Carcinoma
  • Anal Squamous Cell Carcinoma
  • Nasopharyngeal Cancer
  • Gastric Cancer
  • Bladder Cancer
  • Basal Cell Carcinoma
  • Melanoma
  • Bile Duct Cancer
  • Vulvar Cancer
  • Mesothelioma
  • Fallopian Tube Cancer
  • Adnexal Neoplasms
  • Breast Cancer
  • Liver Cancer
  • Non-Small Cell Lung Cancer
  • Squamous Cell Carcinoma
  • Cervical Cancer
  • Ovarian Cancer
  • Thymic Carcinoma
  • Salivary Gland Carcinoma

DUET-2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~56 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 56 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine the safety and tolerability profile of XmAb20717

DUET-2 Trial Design

1Treatment groups
Experimental Treatment
Group I: XmAb20717Experimental Treatment1 Intervention
XmAb20717 administered by intravenous dosing on Days 1 and 15 of each 28-day cycle for a total of two cycles
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
XmAb20717
2018
Completed Phase 1
~150

Find a Location

Who is running the clinical trial?

Xencor, Inc.Lead Sponsor
29 Previous Clinical Trials
2,603 Total Patients Enrolled
ICON plcIndustry Sponsor
80 Previous Clinical Trials
24,954 Total Patients Enrolled
Barbara Hickingbottom, MDStudy DirectorXencor, Inc.
6 Previous Clinical Trials
468 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
2018. "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03517488.
~22 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top